Magnasense AB (publ)
Anders Ingvarsson has extensive experience in the biotechnology and diagnostics sectors, currently serving as the Chief Executive Officer and Board Member at LifeAssays AB since February 2011, and as the Chairman of the Board and Chief Executive Officer at Aegirbio since December 2019. Aegirbio specializes in drug monitoring for biological therapies in autoimmune, oncology, and neurology fields. Anders co-founded Ingvarssonconsulting AB, where management consulting in Clinical Diagnostics and Biotechnology was provided from September 2010 to January 2011. Previously, Anders held senior roles in sales and marketing at ExonHit Therapeutics and Sangtec Molecular Diagnostics, and managed analytical development at LKB. Anders holds a Master of Science in Chemical Engineering from KTH Royal Institute of Technology, completed between 1977 and 1981.
This person is not in any teams
Magnasense AB (publ)
Magnasense, envision a future where nearly everyone could easily and continuously monitor health issues by promoting the development of novel diagnostics. Magnasense aims to increase the supply and sophistication of diagnostic technologies, including the ability to differentiate between diseases that present with similar symptoms, identify the presence of latent infectious agents, and provide practical low-cost monitoring for treatment efficacy and disease recurrence. Magnasense’s ambition is, in addition to bringing to market innovative diagnostic technologies, to make diagnostics: more accessible, easier to use, give accurate and easy transferable results.